Abstract-Mean and pulsatile components of hemodynamic load are related to cardiovascular disease. Vascular growth factors play a fundamental role in vascular remodeling. The links between growth factors and hemodynamic load components are not well described. In 3496 participants from the Framingham Heart Study third generation cohort (mean age: 40Ϯ9 years; 52% women), we related 4 tonometry-derived measures of central arterial load (carotid femoral pulse wave velocity and forward pressure wave, mean arterial pressure, and the global reflection coefficient) to circulating concentrations of angiopoietin 2, its soluble receptor; vascular endothelial growth factor, its soluble receptor; hepatocyte growth factor; insulin-like growth factor 1; and its binding protein 3. Using multivariable linear regression models, adjusted for standard cardiovascular risk factors, serum insulin-like growth factor 1 concentrations were negatively associated with carotid femoral pulse wave velocity, mean arterial pressure, and reflection coefficient (PՅ0.01 for all), whereas serum vascular endothelial growth factor levels were positively associated with carotid femoral pulse wave velocity and mean arterial pressure (PϽ0.04). Serum insulin-like growth factor binding protein 3 and soluble angiopoietin 2 receptor levels were positively related to mean arterial pressure and to forward pressure wave, respectively (PϽ0.05). In our cross-sectional study of a large community-based sample, circulating vascular growth factor levels were related to measures of mean and pulsatile hemodynamic load in a pattern consistent with the known physiological effects of insulin-like growth factor 1 and vascular endothelial growth factor. 
T he arterial tree consists of a serially connected system of large proximal elastic conduit arteries, medium-sized muscular arteries, smaller arteries and arterioles, and the microcirculation. Consequently, arterial function and flow are determined by the complex integration of the physiological properties of these diverse segments of the vasculature. Large artery structure and function are powerful determinants of pulsatile hemodynamic load on the heart. Indeed, increased aortic stiffness is a major correlate of elevated blood pressure, cardiac hypertrophy, and cardiovascular disease (CVD) outcomes. [1] [2] [3] [4] Therefore, evaluation of factors that influence conduit artery function may provide important insights into the pathogenesis of high blood pressure, target organ damage, and CVD.
Numerous studies indicate that vascular structure and function across the arterial tree are influenced by several systemic risk factors and multiple biological pathways. [5] [6] [7] More recently, attention has focused on vascular growth factors and their relations with endothelial cell 8, 9 and vascular smooth muscle function, 10 arterial development and remodeling, [11] [12] [13] and the balance between microvascular rarefaction and neovascularization. [14] [15] [16] [17] For example, vascular endothelial growth factor (VEGF) and angiopoietin pathways are separately responsible for vascular sprouting and maintenance of newly sprouted blood vessels. 15 Insulin-like growth factor 1 (IGF1) is known to stimulate elastin production in the developing aorta. 18 Hepatocyte growth factor (HGF) is known to stabilize vascular endothelium and respond to injury by preventing neointimal proliferation and encouraging healthy endovascular healing in response to injury. 19 Accordingly, we hypothesized that there are bidirectional relations between circulating levels of vascular growth factors and measures of large artery stiffness and hemodynamic load. We tested this hypothesis by examining the crosssectional relations of a complementary panel of circulating vascular growth factors and their soluble receptors and binding proteins with measures of mean and pulsatile hemodynamic load in a large community-based sample.
Methods
The sampling scheme and design of the Framingham Heart Study third generation cohort have been detailed. 20 Briefly, children of the Offspring cohort (and grandchildren of the original Framingham cohort) who belonged to the largest families were recruited between 2002 and 2005. Participants who attended their first examination cycle (2002) (2003) (2004) (2005) were eligible for the present investigation. At that examination, attendees underwent a medical history and physical examination, laboratory testing for standard CVD risk factors, and assessment of arterial stiffness using applanation tonometry. In the present investigation, we evaluated 3496 participants (85% of attendees) who had available tonometry phenotypes, circulating measurements of all 7 vascular growth factors and available covariates for analysis. The study protocol was approved by the Boston University Medical Center Institutional Review Board; written informed consent was obtained from all of the participants.
Circulating Growth Factor Measurements
Fasting venous blood samples were drawn on the morning of the study visit for all of the attendees. Blood specimens were centrifuged and then stored at Ϫ80°C without any freeze-thaw cycles until vascular growth factor assays were performed. Circulating serum concentrations of VEGF, its soluble receptor (soluble fms-like tyrosine kinase), angiopoietin 2 (Ang2) and its soluble receptor (soluble tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 [sTie2]), HGF, IGF1, and its primary binding protein, IGF binding protein 3 (IGFBP3), were assayed using commercial assay kits (R&D Systems, Inc; Minneapolis, MN). Assays were conducted as described previously with use of serum VEGF due to its high correlation with plasma VEGF and intra-assay coefficients of variation ranging between 2.1% for VEGF and 9.1% for IGFBP3.
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Covariate Definitions
Covariates were assessed at the Heart Study examination. Continuous covariates included age, height, weight, body mass index, heart rate, alcohol use (ounces consumed per month), estimated glomerular filtration rate, fasting plasma total cholesterol and high-density lipoprotein cholesterol modeled as the ratio of total:high-density lipoprotein cholesterol, triglycerides, and glucose. Height, weight, and heart rate were specifically included in this analysis because of their effects on tonometric variables. 7 Binary covariates included sex, self-report of smoking within the past year, treatment for hypertension, diabetes mellitus, treatment for hyperlipidemia, and prevalent CVD. We did not adjust the models for blood pressure because a goal of the analyses was to examine growth factor relations with individual components of the blood pressure waveform.
Noninvasive Hemodynamic Data Acquisition and Analysis by Applanation Tonometry
As described previously, participants underwent noninvasive hemodynamic assessment after 5 minutes of rest in a supine position. 24 Four electrocardiographic leads were placed for timing of the cardiac cycle, and auscultatory blood pressures were obtained on the right arm of participants. Arterial tonometry was performed on right-sided carotid, brachial, radial, and femoral arteries using a customized tonometer (Cardiovascular Engineering, Inc, Norwood, MA). Next, 2D echocardiographic images of the left ventricular outflow tract were obtained from a parasternal long-axis view followed by pulsed Doppler of the left ventricular outflow tract from an apical 5-chamber view. Body surface measurements from suprasternal notch to pulse recording sites were obtained by using a fiberglass tape measure for carotid, brachial, and radial sites and a caliper for the femoral site. Arterial waveform signals were digitized (1000 Hz) and transferred to the core laboratory (Cardiovascular Engineering, Inc) where they were analyzed blinded to all of the clinical and risk factor data.
Analysis of arterial waveforms began from the ECG-derived R wave as the referent timing point. Carotid pressure was used as a surrogate for central arterial pressure and was calibrated to diastolic and integrated mean brachial artery waveforms. The peak and trough of signal averaged brachial waveforms were calibrated to the brachial cuff-measured systolic and diastolic blood pressures. The mean arterial pressure (MAP) was calculated by integration of the calibrated brachial pressure waveform. Forward pressure wave (FPW) and reflected pressure wave were separated, and the amplitude (peak minus trough) of each wave was assessed. 25 The global reflection coefficient (RC) was computed as reflected wave amplitude divided by FPW and expressed as a percentage. Carotid-femoral pulse wave velocity (CFPWV) was calculated as described previously. 26 We chose 4 specific vascular measures to capture different aspects of hemodynamic load: pressure pulsatility and matching between flow and diameter (FPW), aortic wall stiffness (CFPWV), global wave reflection (RC), and steady-flow load (MAP). These 4 variables collectively account for nearly all of the variance in pulsatile and steady-state hemodynamic conditions. 27 We chose to evaluate RC rather than a pressure-only measure of wave reflection, such as augmentation index, because augmentation is heavily dependent on a number of important confounders, such as heart rate and left ventricular function. 28 By focusing on FPW and RC, we are able to relate the primary elements of the backward wave to specific growth factors. The high reproducibility of hemodynamic measurement, interobserver consistency, and associations between hemodynamic parameters and CVD risk factors in this cohort have been described previously.
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Statistical Analysis
All of the analyses were sex pooled. The primary predictor variables of interest were the circulating vascular growth factor concentrations, which were natural-logarithmically transformed to normalize their right-skewed distributions. Clinical covariates were modeled as continuous or binary variables, as detailed above. The primary dependent variables of interest were MAP, FPW, RC, and CFPWV, which were considered in separate analyses. CFPWV was inverted (1000/CFPWV) to normalize right skewed variance. To preserve the directionality of growth factor associations with arterial stiffness, all of the effects for associations with inverse CFPWV are expressed per Ϫ1 SD increment. We evaluated the age-and sex-adjusted Pearson correlation coefficients relating growth factor levels to each other and to clinical covariates, including standard CVD risk factors. Next, 2 multivariable linear regression models were constructed to determine associations of the 7 vascular growth factors with each of the 4 hemodynamic variables. First, we constructed separate age-and sex-adjusted linear regression models to assess the associations of the vascular growth factors with each tonometry variable. Then, we constructed a second set of models for each tonometry variable starting with the set of clinical covariates known to be associated with tonometry variables (including age, sex, height, weight, body mass index, heart rate, smoking, hypertension treatment, diabetes mellitus, lipid therapy, total:high-density lipoprotein cholesterol ratio, and triglycerides) followed by introduction of individual growth factors in a forward stepwise procedure using a significance criterion of Ͻ0.1 as an entry criterion. These final models were estimated using generalized estimating equations with a compound symmetry correlation matrix to account for familial correlations. A P value of Ͻ0.05 was used to indicate statistical significance, and all of the analyses were performed using SAS 9.2 (SAS, Cary, NC). All of the authors have reviewed and take responsibility for the article as written.
Results
Baseline Characteristics
The clinical, biochemical, and hemodynamic characteristics of the study sample are summarized in Table 1 . Mean circulating concentrations of HGF, VEGF, soluble fms-like tyrosine kinase, Ang2, sTie2, IGF1, and IGFBP3 were similar in men and women. For the distributions of measured values of the vascular growth factors, please see the online-only Data Supplement.
Covariate-Adjusted Associations of Growth Factors With Tonometric Vascular Measurements
Modest relations were noted between the levels of the growth factors themselves and between the growth factors and the clinical covariates (please see the online-only Data Supplement). The results of age-, sex-, and multivariable-adjusted regression models for each tonometry variable are displayed in Table 2 . Serum HGF, VEGF, and IGFBP3 were positively related, whereas serum Ang2 and IGF1 were negatively related, to MAP in age-and sex-adjusted models. On additional adjustment for standard CVD risk factors, VEGF, serum IGFBP3, and IGF1 remained related to MAP (PՅ0.004 for all).
Serum HGF and sTie2 were positively related to FPW in age-and sex-adjusted models, whereas sTie2 remained associated on multivariable adjustment. Serum Ang2 was positively related but sTie2, serum HGF and IGF1 were negatively related to RC in age-and sex-adjusted models; only serum IGF1 remained related on adjustment for other risk factors. Finally, circulating sTie2, HGF, and VEGF were positively related, whereas IGF1 and Ang2 were negatively related to CFPWV in age-and sex-adjusted models; VEGF and IGF1 remained associated on multivariable adjustment. Because MAP and CFPWV are related and IGF1 and VEGF were jointly associated with both CFPWV and MAP, we further adjusted the CFPWV model for MAP. With this additional adjustment, the association of IGF1 with CFPWV persisted (Ϫ0.84 [95% CI: Ϫ1.49 to Ϫ0.20]; Pϭ0.01), whereas the association with VEGF was no longer statistically significant (Pϭ0.34).
Discussion
Vascular growth factors play a fundamental role in arterial remodeling and microvascular homeostasis, which are key contributors to the pathophysiology of hypertension and target organ damage. In the present investigation, we related a panel of 7 circulating vascular growth factors and their soluble receptors to 4 measures of mean and pulsatile hemodynamic load. Our principal findings are 3-fold. First, circulating growth factors are associated with hemodynamic measures, with growth factors and their soluble receptors or binding proteins generally having opposite directionality of associations. Associations were observed across a concise but comprehensive panel of hemodynamic measures that capture different aspects of vascular function consistent with a broad influence of vascular growth factors. Second, adjustment for standard risk factors attenuated some of the associations observed. It is conceivable that such multivariable modeling may constitute overadjustment, because standard risk factors may influence vascular growth factor levels (please see the online-only Data Supplement), which, in turn, modulate vascular function.
21-23,29-31 Third, IGF1 and VEGF emerged as the 2 growth factors that were related to several measures Values are meanϮSD, unless indicated. BMI indicates body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HGF, hepatocyte growth factor; sFlt, soluble fms-like tyrosine kinase; VEGF, vascular endothelial growth factor; Ang2, angiopoietin 2; sTie2, soluble tyrosine kinase with immunoglobulinlike and epidermal growth factor-like domains 2; IGF1, insulin-like growth factor 1; IGFBP3, insulin like growth factor binding protein 3.
*Data show natural logarithmically transformed biomarkers measured in nanograms per milliliter. See Figure S1 for distributions of growth factors in original units. of vascular function. Specifically, we observed a pattern of negative relations between circulating IGF1 and CFPWV, MAP, and RC but a positive association of VEGF concentrations with CFPWV and MAP. After adjusting for MAP, the relation between VEGF and CFPWV was no longer significant, whereas the inverse association between IGF1 and CFPWV persisted, suggesting a potentially favorable relation between IGF1 and aortic stiffness that is separate from the association with steady-flow load and MAP. Additional findings of interest include the positive relations observed between IGFBP3 with MAP and sTie2 with FPW. Overall, our observations are consistent with the hypothesis that vascular growth factors modulate mean and pulsatile hemodynamic load, consistent with their panarterial effects.
Growth Factors in Vascular Remodeling
Central arterial stiffening is characterized histologically by intimal-medial thickening, with vascular smooth muscle cell (VSMC) proliferation and disorganization, and extracellular matrix remodeling, with an increased collagen I/III content and reduced elastin content. [32] [33] [34] [35] [36] [37] In parallel, peripheral arterial resistance is partly driven by arteriolar myogenic tone and a combination of microvascular remodeling and proliferation of VSMCs. [33] [34] [35] [36] [37] [38] The negative association of IGF1 levels with MAP, CFPWV, and RC is consistent with the known biological effects of this peptide hormone. IGF1 has vasodilatory effects via a nitric oxide-dependent mechanism involving endothelial cells and VSMCs. 9 IGF1 is antiapoptotic and maintains endothelial health. 11 Our findings are also consistent with the graded negative relations between circulating IGF1 levels and hypertension in cohort studies. 39 In addition, genetic variation in an IGF1 promoter region causing low circulating IGF1 concentrations has been associated with greater carotid intimal thickening and higher pulse wave velocity in hypertensive participants. 13 Similarly, growth hormone deficiency All of the growth factors are natural logarithmically transformed and standardized. HGF indicates hepatocyte growth factor; sFlt, soluble fms-like tyrosine kinase; VEGF, vascular endothelial growth factor; Ang2, angiopoietin 2; sTie2, soluble tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2; IGF1, insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding protein 3.
*Multivariable models were adjusted for age, sex, height, weight, body mass index, heart rate, total:high-density lipoprotein cholesterol, triglycerides, diabetes mellitus, hypertension treatment, lipid therapy, and smoking. †Standardized regression coefficients indicate change in mean hemodynamic variable per SD change in log-transformed biomarker. For example, every SD increase in VEGF (1 SDϭ0.8 log-normal unitsϭ2.22 ng/mL) is associated with a 0.47-mm Hg increase in mean arterial pressure, adjusting for clinical risk factors. ‡Effect sizes for growth factors in models of inverse carotid-femoral pulse wave velocity are per Ϫ1 SD, which restores the directionality between growth factors and aortic stiffness. For example, a positive ␤ indicates that higher growth factor levels are associated with higher carotid-femoral pulse wave velocity and greater aortic stiffness.
states with consequent low IGF1 levels are associated with greater vascular stiffness. 40 In a cohort of older adults, IGF1 and IGFBP3 were negatively related to ankle brachial index. 41 Likewise, higher IGFBP3 levels have been associated with greater carotid intimal-medial thickening in hypertensive patients. 42 The positive association of VEGF levels with MAP warrants comment. VEGF modulates vasculogenesis throughout the life course, both in physiological and pathological circumstances. Increased circulating VEGF concentrations have been associated with prevalent CVD and CVD risk factors, including hypertension. 22, 30, 43, 44 Another study reported that VEGF levels were negatively related to carotid distensibility, an index of arterial stiffness, in diabetic and nondiabetic patients. 12 It has been postulated that VEGF levels may increase with increasing CVD risk factor burden to compensate for the effects of increased peripheral resistance, microvascular rarefaction, and increased vascular stiffness. 31, 45, 46 Conversely, VEGF inhibiting therapy is reported to have hypertension as a adverse effect. 47 In vitro work has shown that VEGF stimulates vascular growth to counteract stiffening, 48 inhibits VSMC apoptosis to maintain cell number, 8 and induces VSMC proliferation. 49 Other investigators have demonstrated that VEGF production in pulmonary microvascular endothelial cells is related to the level of flow pulsatility, which is higher in the presence of stiffer large arteries. 50 Relations between large artery stiffness and microvascular function on the one hand 51 and between flow pulsatility and microvascular production of VEGF on the other 50 may contribute to the present observation that VEGF and CFPWV are related. However, those relations appear to be mediated by MAP, which is a measure of microvascular structure and function. VEGF is known to increase tissue vascularization, which should reduce peripheral resistance and MAP. Thus, the observation that higher VEGF levels are associated with higher MAP suggests a compensatory response rather than a primary effect of VEGF on the vasculature.
The contrasts between IGF1 and VEGF, as well as other growth factors, are consistent with their respective roles in biology and the mechanisms of their dynamic regulation. IGF1 concentration is largely a function of the pituitary output of growth hormone and biologically regulates organ and organism size through growth effects on tissues. 52 The vascular effects of IGF1 are interpretable as a necessary process to facilitate nutrient flow to allow for tissue growth. Indirect effects on vasculature may stem from improved glucose homeostasis. 53 In contrast, VEGF is produced by tissues in response to reduced oxygen tension to promote increased vascular flow and to reduce tissue starvation. 54 The positive associations of HGF with MAP, FPW, and CFPWV and the negative association with RC in age-and sex-adjusted models are consistent with the diverse effects of this peptide on vasculature.
14, 55 The attenuation of these associations on multivariable adjustment may reflect the moderate association of circulating HGF levels with CVD risk factors. 22 The negative association of Ang2 with MAP and CFPWV but the positive association of its soluble receptor, sTie2, with CFPWV in age-and sex-adjusted models are consistent with the complex role of the Ang2-Tie2 system on vasculature, in part dependent on the actions of angiopoietin 1 and VEGF. [15] [16] [17] 45, 46 Ang2 levels are known to be regulated by the competition of sTie2 versus cell-bound Tie2. Ang2 actions are facilitated by its competition with angiopoietin 1 and synergy with VEGF. Overall, Ang2 promotes neovascular sprouting, enhances neovascular stability, and promotes adaptive remodeling. 15, 56 Consistent with their antagonism, Ang2 and sTie2 had generally opposite associations with hemodynamic variables. The opposite associations of Ang2 with CFPWV versus RC are consistent with the observation that as aortic stiffness increases, impedance mismatch between central and peripheral arteries decreases, thereby decreasing RC. 24 Also, the inverse relation between MAP and Ang2 may be consistent with a positive role in neovascular number and stability. 15 In parallel, mismatch of aortic material properties to loading conditions may be explained by inadequate Ang2 signaling given the direct relation between the Ang2 negative regulator sTie2 and FPW. However, after multivariable adjustment, these crosssectional associations of sTie2 with FPW and VEGF with CFPWV are only marginally significant and will require further investigation.
Limitations
This study was conducted in a predominantly white, middleaged, population-based cohort. These findings may not be generalizable to other ethnicities. Causation cannot be inferred from the modest associations seen in this crosssectional study. We did not correct for multiple statistical testing and report all of the nominally significant relations. Consequently, several of the associations reported here should be viewed as hypothesis generating and warrant replication in other samples.
Perspectives
In this cross-sectional observational cohort of middle-aged adults, vascular growth factors were found to be associated with components of pulsatile and steady-state hemodynamic load. Consistent with previous reports, circulating levels of IGF1 were generally inversely related to MAP and pulse wave velocity, whereas circulating VEGF concentrations were directly associated with these hemodynamic parameters. These data suggest that similar vasoactive pathways are at work in both large and small arteries. Future work may be able to discern the temporal relation of hemodynamic variables to growth factor alterations and to illuminate causality.
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